| 92 | 0 | 22 |
| 下载次数 | 被引频次 | 阅读次数 |
<正>患者男性,72岁,因"黑便、乏力2个月"入我院。患者入院2个月前无明显诱因出现黑便,约300 g/d,伴乏力,进食不少,曾在当地医院查血常规示Hb 70 g/L,因当地病理结果不确定,遂来我院。入院后复查胃镜示:胃体前壁、胃体小弯及胃底见一巨大隆起,表面凹凸不平,可见溃疡形成,周围环堤样隆起。病理结果示:胃间质瘤;免疫组化:CD117(+)、CD34(+)、Dog-1(+)、Ki-67(30%)、SMA(–)、S-100(–)。
Abstract：[1] Florou V,Wilky BA,Trent JC. Latest advances in adult gastrointestinal stromal tumors[J]. Future Oncol,2017,13(24):2183-2193.
[2] Blay JY,Shen L,Kang YK,et al. Nilotinib versus imatinibas first-line therapy for patients with unresectable ormetastatic gastrointestinal stromal tumours(ENESTg1):arandomised phase 3trial[J]. Lancet Oncol,2015,16(5):550-560.
[3] Khoo TL,Catalano A,Supple S,et al. Hyperpigmentation of thehard palate associated with imatinib therapy for chronic myeloidleukemia with a genetic variation in the proto-oncogene c-KIT[J].Leuk Lymphoma,2013,54(1):186-188.
[4] Guo Y,Liu J,Wang F,et al. The role of surgical resection following tyrosine kinase inhibitors treatment in patients with advanced gastrointestinal stromal tumors:a systematic review and Meta-analysis[J]. J Cancer,2019,10(23):5785-5792.
[5] Attanoos RL,Alchami FS,Pooley FD,et al. Usual interstitial pneumonia in asbestos-exposed cohorts concurrent idiopathic pulmonary fibrosis or atypical asbestosis[J]. Histopathology,2016,69(3):492-498.
[6] Skolnik K,Ryerson CJ. Unclassifiable interstitial lung disease:a review[J]. Respirology,2016,21(1):51-56.
[7] Ohnishi K,Sakai F,Kudoh S,et al. Twenty-seven cases of druginduced interstitial lung disease associated with imatinib mesylate[J]. Leukemia,2006,20(6):1162-1164.
[8] Lee NR,Jang JW,Kim HS,et al. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection[J]. Korean J Intern Med,2015,30(4):550-553.
[9]黄敬敬，王彦云，徐恩斌.格列卫治疗小肠间质肉瘤导致肺间质纤维化1例[J].临床医药文献杂志，2016,3(12):2426.
[10] Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease:clinical features,diagnostic challenges,and therapeutic dilemmas[J]. Drug Saf,2016,39(11):1073-1091.
[11] Grimison P,Goldstein D,Schneeweiss J,et al. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge,and potential causative mechanisms[J]. Intern Med J,2005,35(2):136-137.
[12] Yamasawa H,Sugiyama Y,Bando M,et al. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis[J]. Respiration, 2008,75(3):350-354.
[13] Go SW,Kim BK,Lee SH,et al. Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis[J]. Tuberc Respir Dis(Seoul),2013,75(6):256-259.
[14] Seki N,Ito A,Watanabe K,et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration[J]. Intern Med,2007,46(23):1941-1942.
[15] Delomas T,DarnéC,Besson C. Lack of recurrence of imatinibinduced interstitial lung disease with nilotinib[J]. Leuk Lymphoma,2012,53(2):332-333.
基本信息:
中图分类号:R735.2;R563.9
引用信息:
[1]张怡婧,梁铁军.伊马替尼治疗胃间质瘤致肺间质纤维化1例报告[J].老年医学研究,2020,1(02):46-47.
2020-12-25
2020-12-25